Patents by Inventor Philippe Talaga

Philippe Talaga has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11911452
    Abstract: Provided are mixed carrier, multivalent pneumococcal conjugate compositions comprising 21 different pneumococcal capsular polysaccharide-protein conjugates, wherein each of the conjugates includes a capsular polysaccharide from a different serotype of Streptococcus pneumoniae conjugated to either tetanus toxoid (TT) or CRM197, wherein the Streptococcus pneumoniae serotypes are selected from 1, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11 A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F, where the capsular polysaccharides of two of serotypes 1, 3, and 5 and one or both of serotypes 15B and 22F are conjugated to TT and the remaining capsular polysaccharides are conjugated to CRM197. Also provided are methods of producing the mixed carrier, multivalent pneumococcal conjugate compositions and methods of using the same for prophylaxis against Streptococcus pneumoniae infection or disease in a subject.
    Type: Grant
    Filed: September 10, 2021
    Date of Patent: February 27, 2024
    Assignees: SANOFI PASTEUR INC., SK BIOSCIENCE CO., LTD.
    Inventors: Kyungjun An, Dongsoo Ham, Hun Kim, Sunghyun Kim, Jinhwan Shin, Robert Hopfer, Richard D. Kensinger, Moe Kyaw, Philippe Talaga
  • Patent number: 11554170
    Abstract: The present invention provides for novel immunological and vaccine formulations comprising a newly applied non-crosslinked polyacrylic acid polymer adjuvant. The adjuvants may be combined with a wide variety of immunogens to produce vaccines that are safe and effective when administered to a wide range of target animals. The immunogens may include, but are not limited to: inactivated pathogens, attenuated pathogens, subunits, recombinant expression vectors, plasmids or combinations thereof. The animals may include, but are not limited to: humans, murine, canines, felines, equines, porcines, ovines, caprines and bovines.
    Type: Grant
    Filed: June 15, 2017
    Date of Patent: January 17, 2023
    Assignees: Sanofi Pasteur SA, Boehringer Ingelheim Animal Health USA Inc.
    Inventors: Guillaume Rigaut, Alexis Guy André Lucien Parisot, Karelle De Luca, Christine Michele Pierrette Andreoni, Lydie Remolue, Marie Garinot, Jean-François Cotte, Patricia Probeck-Quellec, Jean Haensler, Véronique Chambon, Philippe Talaga
  • Publication number: 20220265803
    Abstract: Provided are multivalent pneumococcal conjugate compositions comprising 22-27 different pneumococcal capsular polysaccharide-protein conjugates, wherein each pneumococcal capsular polysaccharide-protein conjugate comprises a protein carrier conjugated to a capsular polysaccharide from a different serotype of Streptococcus pneumoniae, wherein the Streptococcus pneumoniae CA serotypes are selected from 1, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10 A, 11 A, 12F, 14, 15A, 15B, 15C, 18C, 19A, 19F, 22F, 23 A, 23B, 23F, 24F, 33F, and 35B. Also provided are methods of producing the multivalent pneumococcal conjugate compositions and methods of using the same for prophylaxis against Streptococcus pneumoniae infection or disease in a subject. Also provided are immunogenic compositions comprising at least one polysaccharide-protein conjugate wherein the polysaccharide is a capsular polysaccharide from CN Streptococcus pneumoniae serotype 15A, 15C, 23 A, 23B, 24F, and/or 35B and methods of preparing the same.
    Type: Application
    Filed: July 27, 2020
    Publication date: August 25, 2022
    Inventors: Kyungjun AN, Hun KIM, Sunghyun KIM, Moe KYAW, Jeong-min LEE, Jinhwan SHIN, Philippe TALAGA
  • Patent number: 11241489
    Abstract: Provided are mixed carrier, multivalent pneumococcal conjugate compositions comprising 20 different pneumococcal capsular polysaccharide-protein conjugates, wherein each of the conjugates includes a capsular polysaccharide from a different serotype of Streptococcus pneumoniae conjugated to either tetanus toxoid or CRM197, wherein the Streptococcus pneumoniae serotypes are selected from 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F, wherein two of the capsular polysaccharides are conjugated to tetanus toxoid and the remaining capsular polysaccharides are conjugated to CRMig7, and wherein the two capsular polysaccharides that are conjugated to tetanus toxoid are selected from the group consisting of serotypes 1, 3, and 5. Also provided are methods of producing the mixed carrier, multivalent pneumococcal conjugate compositions and methods of using the same for prophylaxis against Streptococcus pneumoniae infection or disease in a subject.
    Type: Grant
    Filed: August 4, 2017
    Date of Patent: February 8, 2022
    Assignees: SANOFI PASTEUR INC., SK BIOSCIENCE CO., LTD.
    Inventors: Kyungjun An, Wooyoung Choi, Dongsoo Ham, Hun Kim, Jinhwan Shin, Robert Hopfer, Richard D. Kensinger, Moe Kyaw, Eric Desauziers, Clotilde El Guerche Seblain, Philippe Talaga
  • Publication number: 20220031828
    Abstract: Provided are mixed carrier, multivalent pneumococcal conjugate compositions comprising 21 different pneumococcal capsular polysaccharide-protein conjugates, wherein each of the conjugates includes a capsular polysaccharide from a different serotype of Streptococcus pneumoniae conjugated to either tetanus toxoid (TT) or CRM197, wherein the Streptococcus pneumoniae serotypes are selected from 1, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F, where the capsular polysaccharides of serotypes two of serotypes 1, 3, and 5 are conjugated to TT and the remaining capsular polysaccharides are conjugated to CRM197. Also provided are methods of producing the mixed carrier, multivalent pneumococcal conjugate compositions and methods of using the same for prophylaxis against Streptococcus pneumoniae infection or disease in a subject.
    Type: Application
    Filed: October 13, 2021
    Publication date: February 3, 2022
    Inventors: Kyungjun AN, Dongsoo HAM, Hun KIM, Sunghyun KIM, Jinhwan SHIN, Robert HOPFER, Richard D. KENSINGER, Moe KYAW, Philippe TALAGA
  • Patent number: 11224652
    Abstract: Provided are mixed carrier, multivalent pneumococcal conjugate compositions comprising 16 different pneumococcal capsular polysaccharide-protein conjugates, wherein each of the conjugates includes a capsular polysaccharide from a different serotype of Streptococcus pneumoniae conjugated to either tetanus toxoid or CRM197, wherein the Streptococcus pneumoniae serotypes are selected from 1, 3, 4, 5, 6A, 6B, 7F, 9V, 12F, 14, 18C, 19A, 19F, 22F, 23F, and 33F, wherein two of the capsular polysaccharides are conjugated to tetanus toxoid and the remaining capsular polysaccharides are conjugated to CRM197, and wherein the two capsular polysaccharides that are conjugated to tetanus toxoid are selected from the group consisting of serotypes 1, 3, and 5. Also provided are methods of producing the mixed carrier, multivalent pneumococcal conjugate compositions and methods of using the same for prophylaxis against Streptococcus pneumoniae infection or disease in a subject.
    Type: Grant
    Filed: August 4, 2017
    Date of Patent: January 18, 2022
    Assignees: SANOFI PASTEUR INC., SK BIOSCIENCE CO., LTD.
    Inventors: Kyungjun An, Wooyoung Choi, Dongsoo Ham, Hun Kim, Jinhwan Shin, Robert Hopfer, Richard D. Kensinger, Moe Kyaw, Eric Desauziers, Clotilde El Guerche Seblain, Philippe Talaga
  • Publication number: 20210401963
    Abstract: Provided are mixed carrier, multivalent pneumococcal conjugate compositions comprising 21 different pneumococcal capsular polysaccharide-protein conjugates, wherein each of the conjugates includes a capsular polysaccharide from a different serotype of Streptococcus pneumoniae conjugated to either tetanus toxoid (TT) or CRM197, wherein the Streptococcus pneumoniae serotypes are selected from 1, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11 A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F, where the capsular polysaccharides of two of serotypes 1, 3, and 5 and one or both of serotypes 15B and 22F are conjugated to TT and the remaining capsular polysaccharides are conjugated to CRM197. Also provided are methods of producing the mixed carrier, multivalent pneumococcal conjugate compositions and methods of using the same for prophylaxis against Streptococcus pneumoniae infection or disease in a subject.
    Type: Application
    Filed: September 10, 2021
    Publication date: December 30, 2021
    Inventors: Kyungjun AN, Dongsoo HAM, Hun KIM, Sunghyun KIM, Jinhwan SHIN, Robert HOPFER, Richard D. KENSINGER, Moe KYAW, Philippe TALAGA
  • Patent number: 11147864
    Abstract: Provided are mixed carrier, multivalent pneumococcal conjugate compositions comprising 21 different pneumococcal capsular polysaccharide-protein conjugates, wherein each of the conjugates includes a capsular polysaccharide from a different serotype of Streptococcus pneumoniae conjugated to either tetanus toxoid (TT) or CRM197, wherein the Streptococcus pneumoniae serotypes are selected from 1, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11 A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F, where the capsular polysaccharides of serotypes two of serotypes 1, 3, and 5 are conjugated to TT and the remaining capsular polysaccharides are conjugated to CRM197. Also provided are methods of producing the mixed carrier, multivalent pneumococcal conjugate compositions and methods of using the same for prophylaxis against Streptococcus pneumoniae infection or disease in a subject.
    Type: Grant
    Filed: February 4, 2019
    Date of Patent: October 19, 2021
    Assignees: SANOFI PASTEUR INC., SK BIOSCIENCE CO., LTD.
    Inventors: Kyungjun An, Dongsoo Ham, Hun Kim, Sunghyun Kim, Jinhwan Shin, Robert Hopfer, Richard D. Kensinger, Moe Kyaw, Philippe Talaga
  • Patent number: 11123417
    Abstract: Provided are mixed carrier, multivalent pneumococcal conjugate compositions comprising 21 different pneumococcal capsular polysaccharide-protein conjugates, wherein each of the conjugates includes a capsular polysaccharide from a different serotype of Streptococcus pneumoniae conjugated to either tetanus toxoid (TT) or CRM197, wherein the Streptococcus pneumoniae serotypes are selected from 1, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11 A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F, where the capsular polysaccharides of two of serotypes 1, 3, and 5 and one or both of serotypes 15B and 22F are conjugated to TT and the remaining capsular polysaccharides are conjugated to CRM197. Also provided are methods of producing the mixed carrier, multivalent pneumococcal conjugate compositions and methods of using the same for prophylaxis against Streptococcus pneumoniae infection or disease in a subject.
    Type: Grant
    Filed: February 4, 2019
    Date of Patent: September 21, 2021
    Assignees: SANOFI PASTEUR INC., SK BIOSCIENCE CO., LTD.
    Inventors: Kyungjun An, Dongsoo Ham, Hun Kim, Sunghyun Kim, Jinhwan Shin, Robert Hopfer, Richard D. Kensinger, Moe Kyaw, Philippe Talaga
  • Publication number: 20210077608
    Abstract: Provided are mixed carrier, multivalent pneumococcal conjugate compositions comprising 21 different pneumococcal capsular polysaccharide-protein conjugates, wherein each of the conjugates includes a capsular polysaccharide from a different serotype of Streptococcus pneumoniae conjugated to either tetanus toxoid (TT) or CRM197, wherein the Streptococcus pneumoniae serotypes are selected from 1, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11 A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F, where the capsular polysaccharides of two of serotypes 1, 3, and 5 and one or both of serotypes 15B and 22F are conjugated to TT and the remaining capsular polysaccharides are conjugated to CRM197. Also provided are methods of producing the mixed carrier, multivalent pneumococcal conjugate compositions and methods of using the same for prophylaxis against Streptococcus pneumoniae infection or disease in a subject.
    Type: Application
    Filed: February 4, 2019
    Publication date: March 18, 2021
    Inventors: Kyungjun AN, Dongsoo HAM, Hun KIM, Sunghyun KIM, Jinhwan SHIN, Robert HOPFER, Richard D. KENSINGER, Moe KYAW, Philippe TALAGA
  • Publication number: 20200360502
    Abstract: Provided are mixed carrier, multivalent pneumococcal conjugate compositions comprising 21 different pneumococcal capsular polysaccharide-protein conjugates, wherein each of the conjugates includes a capsular polysaccharide from a different serotype of Streptococcus pneumoniae conjugated to either tetanus toxoid (TT) or CRM197, wherein the Streptococcus pneumoniae serotypes are selected from 1, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11 A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F, where the capsular polysaccharides of serotypes two of serotypes 1, 3, and 5 are conjugated to TT and the remaining capsular polysaccharides are conjugated to CRM197. Also provided are methods of producing the mixed carrier, multivalent pneumococcal conjugate compositions and methods of using the same for prophylaxis against Streptococcus pneumoniae infection or disease in a subject.
    Type: Application
    Filed: February 4, 2019
    Publication date: November 19, 2020
    Inventors: Kyungjun AN, Dongsoo HAM, Hun KIM, Sunghyun KIM, Jinhwan SHIN, Robert HOPFER, Richard D. KENSINGER, Moe KYAW, Philippe TALAGA
  • Patent number: 10772946
    Abstract: The invention relates to a conjugate of a saccharide covalently bound to a carrier protein, wherein the saccharide comprises repetitive units of 1,5 ribitol phosphate in which all the ribitol residues are substituted by N-acetyl D-glucosaminyl residues at the 4-position, and wherein said N-acetyl D-glucosaminyl residues are exclusively in anomeric configuration ? or are exclusively in anomeric configuration ? and wherein the carrier protein provides at least one epitope to the conjugate which is recognized by T helper lymphocytes.
    Type: Grant
    Filed: October 13, 2016
    Date of Patent: September 15, 2020
    Assignee: SANOFI PASTEUR
    Inventors: Pierre-Alexandre Driguez, Nathalie Guillo, Bachra Rokbi, Noëlle Mistretta, Philippe Talaga
  • Publication number: 20200237889
    Abstract: Provided are mixed carrier, multivalent pneumococcal conjugate compositions comprising 20 different pneumococcal capsular polysaccharide-protein conjugates, wherein each of the conjugates includes a capsular polysaccharide from a different serotype of Streptococcus pneumoniae conjugated to either tetanus toxoid or CRM197, wherein the Streptococcus pneumoniae serotypes are selected from 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F, wherein two of the capsular polysaccharides are conjugated to tetanus toxoid and the remaining capsular polysaccharides are conjugated to CRMig7, and wherein the two capsular polysaccharides that are conjugated to tetanus toxoid are selected from the group consisting of serotypes 1, 3, and 5. Also provided are methods of producing the mixed carrier, multivalent pneumococcal conjugate compositions and methods of using the same for prophylaxis against Streptococcus pneumoniae infection or disease in a subject.
    Type: Application
    Filed: August 4, 2017
    Publication date: July 30, 2020
    Inventors: Kyungjun AN, Wooyoung CHOI, Dongsoo HAM, Hun KIM, Jinhwan SHIN, Robert HOPFER, Richard D. KENSINGER, Moe KYAW, Eric DESAUZIERS, Clotilde EL GUERCHE SEBLAIN, Philippe TALAGA
  • Publication number: 20200230233
    Abstract: Provided are mixed carrier, multivalent pneumococcal conjugate compositions comprising 16 different pneumococcal capsular polysaccharide-protein conjugates, wherein each of the conjugates includes a capsular polysaccharide from a different serotype of Streptococcus pneumoniae conjugated to either tetanus toxoid or CRM197, wherein the Streptococcus pneumoniae serotypes are selected from 1, 3, 4, 5, 6A, 6B, 7F, 9V, 12F, 14, 18C, 19A, 19F, 22F, 23F, and 33F, wherein two of the capsular polysaccharides are conjugated to tetanus toxoid and the remaining capsular polysaccharides are conjugated to CRM197, and wherein the two capsular polysaccharides that are conjugated to tetanus toxoid are selected from the group consisting of serotypes 1, 3, and 5. Also provided are methods of producing the mixed carrier, multivalent pneumococcal conjugate compositions and methods of using the same for prophylaxis against Streptococcus pneumoniae infection or disease in a subject.
    Type: Application
    Filed: August 4, 2017
    Publication date: July 23, 2020
    Inventors: Kyungjun AN, Wooyoung CHOI, Dongsoo HAM, Hun KIM, Jinhwan SHIN, Robert HOPFER, Richard D. KENSINGER, Moe KYAW, Eric DESAUZIERS, Clotilde EL GUERCHE SEBLAIN, Philippe TALAGA
  • Publication number: 20180280491
    Abstract: The invention relates to a conjugate of a saccharide covalently bound to a carrier protein, wherein the saccharide comprises repetitive units of 1,5 ribitol phosphate in which all the ribitol residues are substituted by N-acetyl D-glucosaminyl residues at the 4-position, and wherein said N-acetyl D-glucosaminyl residues are exclusively in anomeric configuration ? or are exclusively in anomeric configuration ? and wherein the carrier protein provides at least one epitope to the conjugate which is recognized by T helper lymphocytes.
    Type: Application
    Filed: October 13, 2016
    Publication date: October 4, 2018
    Applicant: SANOFI PASTEUR
    Inventors: Pierre-Alexandre DRIGUEZ, Nathalie GUILLO, Bachra ROKBI, Noëlle MISTRETTA, Philippe TALAGA
  • Publication number: 20170360923
    Abstract: The present invention provides for novel immunological and vaccine formulations comprising a newly applied non-crosslinked polyacrylic acid polymer adjuvant. The adjuvants may be combined with a wide variety of immunogens to produce vaccines that are safe and effective when administered to a wide range of target animals. The immunogens may include, but are not limited to: inactivated pathogens, attenuated pathogens, subunits, recombinant expression vectors, plasmids or combinations thereof. The animals may include, but are not limited to: humans, murine, canines, felines, equines, porcines, ovines, caprines and bovines.
    Type: Application
    Filed: June 15, 2017
    Publication date: December 21, 2017
    Applicants: MERIAL INC., Sanofi Pasteur
    Inventors: Guillaume Rigaut, Alexis Guy André Lucien Parisot, Karelle De Luca, Christine Michele Pierrette Andreoni, Lydie Remolue, Marie Garinot, Jean-François Cotte, Patricia Probeck-Quellec, Jean Haensler, Véronique Chambon, Philippe Talaga
  • Patent number: 8338137
    Abstract: The invention relates to the type 5 and type 8 capsular polysaccharides produced by overproducing S. aureus strains, and also to the immunogenic compositions and the vaccines comprising said capsular polysaccharides.
    Type: Grant
    Filed: March 19, 2007
    Date of Patent: December 25, 2012
    Assignee: Sanofi Pasteur S.A.
    Inventors: Bachra Rokbi, Claude Meric, Noelle Mistretta, Philippe Talaga, Olivier Adam
  • Publication number: 20110052624
    Abstract: The invention relates to the type 5 and type 8 capsular polysaccharides produced by overproducing S. aureus strains, and also to the immunogenic compositions and the vaccines comprising said capsular polysaccharides.
    Type: Application
    Filed: March 19, 2007
    Publication date: March 3, 2011
    Applicant: SANOFI PASTEUR SA
    Inventors: Bachra Rokbi, Claude Meric, Noelle Mistretta, Philippe Talaga, Olivier Adam
  • Patent number: 7320874
    Abstract: The invention relates to a method for assaying the teichoic acids present, most commonly in residual form, in a preparation of Gram+ bacterial antigens. This method requires, first of all, a controlled hydrolysis with hydrofluoric acid at a temperature of less than or equal to 40° C., in order to release the oligosaccharides specific for teichoic acids. The assaying of the specific oligosaccharides can then be carried out by various techniques, in particular by high performance chromatography coupled with pulsed amperometric detection (HPAEC-PAD). The method according to the invention can in particular be used to assay the residual amounts of teichoic acids present in preparations containing capsular polysaccharides of Streptococcus pneumoniae, which may be useful as vaccines.
    Type: Grant
    Filed: July 6, 2004
    Date of Patent: January 22, 2008
    Assignee: Aventis Pasteur SA
    Inventors: Philippe Talaga, Patricia Sepulcri, Sandrine Vialle-Blanc
  • Publication number: 20050009121
    Abstract: The invention relates to a method for assaying the teichoic acids present, most commonly in residual form, in a preparation of Gram+ bacterial antigens. This method requires, first of all, a controlled hydrolysis with hydrofluoric acid at a temperature of less than or equal to 40° C., in order to release the oligosaccharides specific for teichoic acids. The assaying of the specific oligosaccharides can then be carried out by various techniques, in particular by high performance chromatography coupled with pulsed amperometric detection (HPAEC-PAD). The method according to the invention can in particular be used to assay the residual amounts of teichoic acids present in preparations containing capsular polysaccharides of Streptococcus pneumoniae, which may be useful as vaccines.
    Type: Application
    Filed: July 6, 2004
    Publication date: January 13, 2005
    Inventors: Philippe Talaga, Patricia Sepulcri, Sandrine Vialle-Blanc